CT-179
Glioblastoma (recurrent and newly diagnosed)
Key Facts
About Curtana Pharmaceuticals
Curtana Pharmaceuticals is a privately held biotech focused on developing OLIG2-targeted therapies for glioblastoma and medulloblastoma, cancers with poor prognoses. Its lead asset, CT-179, has received FDA Fast Track and Orphan/Rare Pediatric Disease designations, with Phase 1 trials imminent. Founded on pioneering academic research, the company is backed by venture capital and a significant CPRIT grant, positioning it to advance a novel mechanism in neuro-oncology.
View full company profileAbout Curtana Pharmaceuticals
Curtana Pharmaceuticals is a privately held biotech focused on developing OLIG2-targeted therapies for glioblastoma and medulloblastoma, cancers with poor prognoses. Its lead asset, CT-179, has received FDA Fast Track and Orphan/Rare Pediatric Disease designations, with Phase 1 trials imminent. Founded on pioneering academic research, the company is backed by venture capital and a significant CPRIT grant, positioning it to advance a novel mechanism in neuro-oncology.
View full company profile